

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Renal disease</b>				
Renal disease	MicroRNA-193a (miR-193a)	<p>Patient tissue and mouse studies suggest antagonizing miR-193a could help treat focal segmental glomerulosclerosis (FSGS), which can lead to renal failure. Patients with FSGS showed greater expression of miR-193a in glomeruli than healthy individuals. In mice, transgenic expression of miR-193a induced FSGS pathology. Next steps include testing the effects of targeting miR-193a with locked RNA in a mouse model.</p> <p><b>SciBX 6(15); doi:10.1038/scibx.2013.372</b> Published online April 18, 2013</p>	Patent application filed; available for licensing	<p>Gebeshuber, C.A. <i>et al. Nat. Med.</i>; published online March 17, 2013; doi:10.1038/nm.3142</p> <p><b>Contact:</b> Dontscho Kerjaschki, Medical University of Vienna, Vienna, Austria e-mail: <a href="mailto:dontscho.kerjaschki@meduniwien.ac.at">dontscho.kerjaschki@meduniwien.ac.at</a></p>